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ABSTRACT
Background: Multidrug-resistant tuberculosis (MDR-TB) has a socioeconomic impact and threatens
global public health. We assessed treatment outcomes of MDR-TB and predictors of poor treatment
outcomes in Sudan given current high prevalence rates.
Methods: Combined retrospective and prospective cohort study at Abu-Anga hospital (TB specialized
hospital in Sudan). All patients with MDR-TB between 2013 and 2017 were targeted.
Results: A total of 156 patients were recruited as having good records, 117 (75%) were male, and 152
(97.4%) had pulmonary TB. Patients were followed for a median of 18 months and a total of 2108
person-months. The overall success rate was 63.5% and the mortality rate was 14.1%. Rural residency (P
< 0.05) and relapsing on previous treatments (P < 0.05) were determinants of time to poor MDR-TB
treatment outcomes.
Conclusion: Overall, more attention needs to be given to special MDR-TB groups that are highly
susceptible to poor outcomes, i.e. rural patients. As a result, it is highly recommended to maintain
total coverage of medicines for all MDR-TB patients for the entire period of treatment in Sudan. It is also
recommended to instigate more treatment centers in rural areas in Sudan together with programs to
enhance adherence to treatments including patient counseling to improve future outcomes.
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The World Health Organization (WHO) believes over 10 million
people globally fell ill with tuberculosis (TB) in 2017 and 2018,
although the number actually reported is only 7 million [1,2].
Drug-resistant TB continues to be a global public health con-
cern with approximately 580,000 cases worldwide and mortal-
ity worse than most cancers [1,3–6]. Overall, TB is the leading
cause of death among patients with infectious diseases [7,8].
TB is also costly to treat [4,6,9]. In 2015, approximately 480,000
multidrug-resistant tuberculosis (MDR-TB) new cases were
notified with 100,000 incidents registered as rifampicin resis-
tant (RR) world-wide, with 250,000 deaths due to MDR/RR-TB
[6]. In 2018, there were approximately 500,000 new cases of
rifampicin-resistant TB of which 78% were MDR-TB [1].
Previously, the WHO believed that only approximately 25–
30% of MDR-TB cases were detected and only approximately
25% of patients accessed second-line medications globally
[10]. More recently, progress has been made in testing, detect-
ing and treating MDR/RR-TB resulting in 51% of patients with
bacteriologically confirmed TB tested for rifampicin resistance
[1]. Despite this progress though, the number of patients
actually treated in 2017 and 2018 was only one in three
(32%) of approximately 500,000 patients who developed
MDR/RR-TB [1,2]. Furthermore, only approximately 50% of
those who had received treatment were declared successfully
treated [10]. This has risen to 56% with more recent data [1]. In
2017 in Sudan, it was estimated there were 600 MDR/RR-TB
among notified pulmonary TB patients. Moreover, it was esti-
mated that 3.5% of new TB cases and 18% of previously
treated cases are MDR/RR-TB cases [11].
TB-drug resistance generally occurs due to prescribing mal-
practice and poor adherence to anti-TB medications, with the
spread of resistance enhanced by HIV co-infection [3,12,13].
The consequences of primary infection can also result in drug
resistance. Consequently, intensive interventions are typically
needed to address this. MDR-TB is characterized by the high
cost of treatment, longer duration of therapy, low efficacy
compared to susceptible medications, and greater side-effects
of treatment [14]. MDR-TB can be prevented bearing in mind
that an appreciable number of controlled trials have shown
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that a 6-month regimen of rifampicin, pyrazinamide, isoniazid,
and streptomycin or ethambutol is capable of combating TB
with more than 95% of cases reported cured [15].
Overall, the treatment of MDR-TB takes a long time when
compared with susceptible TB, and demands administration of
at least four second-line anti-TB drugs (SLDs), including par-
enteral medicines plus pyrazinamide in the intensive phase
[16]. However, in view of the costs involved and concerns with
adherence, the management of MDR-TB needs both financial
and human resources [2,17]. More recently though, the WHO
has advocated oral-only treatment regimens to improve
adherence rates along with continued patient centered sup-
port programs [18]. Fluoroquinolones, bedaquiline, and line-
zolid are also strongly recommended for use in longer
regimens, with tailored treatments including shorter regimens
also recommended in some patients to help improve adher-
ence and reduce costs [8,18].
Treatment success of MDR-TB relies on the conversion of
the sputum smear of the acid-fast bacilli. The status of myco-
bacterial cultures is needed for follow-up of treatment in
limited resource areas as the findings are considered a robust
interim measure for effective treatment [19]. Overall, sputum
culture conversion plays a crucial role in the treatment success
of MDR-TB [20]. The inability of sputum conversion to negative
by the end of the intensive phase of treatment tends to yield
poor treatment outcomes, namely failure and death [21,22].
The prescribing of SLDs began for MDR-TB patients in
Sudan in 2008, where the program was adopted for presump-
tive diagnosis and empirical treatment of such cases. The
Green Light Committee (GLC) Initiative Document was signed
in 2010 to control MDR-TB by affording access to high-quality
SLDs [23]. In Sudan, the treatment of MDR-TB patients is
provided at Abu-Anga hospital, Khartoum, for at least 18
months. Medicines including ciprofloxacin, ofloxacin, cycloser-
ine, ethionamide, and amikacin are available free of charge to
patients to assist with effective treatment [24]. This compares
with high levels of patient co-payment for medicines that is
typically the case in developing countries [25].
Improving MDR-TB treatment outcomes is one of the five
priority actions suggested by the World Health Organization
(WHO) to address the global threat of MDR-TB [2], with a goal
of a 75% success rate by the end of 2015 [7,17]. By 2030, the
goal is a 90% reduction in the absolute number of deaths due
to TB versus 2015 levels achieved for instance by improved
identification and management of MDR/RR-TB cases helped by
new treatment guidelines from the WHO [2,18]. This includes
the provision of only orally administered medicines and more
tailored treatments to improve compliance [8,18]. In the litera-
ture, there are several factors that affect treatment outcomes.
For example, early culture conversion by the end of the first 2
months is associated with better MDR-TB treatment outcomes
and vice versa [26]. Moreover, a recent study from China
reported that MDR-TB patients who drink, smoke, have oflox-
acin resistance, or a high smear grade, were significantly more
prone to poor treatment outcomes [27]. Furthermore, it has
been reported that male gender, urban residency, aged
between 35 and 44 years, and persistence of culture positivity
at 2 months were predictors of poor MDR-TB treatment out-
comes in Ethiopia [28]. Additionally, extensive drug-resistant
TB (XDR), male gender, and a positive smear at the beginning
of treatment predicted poor treatment outcomes among
Korean patients [29].
However, to date, there have only been a few studies on
the outcomes of treatment of patients with MDR-TB in limited
resource settings with high prevalence rates such as Sudan
[30–33]. We are aware that there have been recent studies
researching the incidence of TB as well as success rates for
smear-positive TB between different parts of Sudan [34], rea-
sons why TB patients default on their treatment including
rural areas, adverse effects of treatment and previous history
of TB [35], and that treatment outcomes in Sudan appear to be
lagging behind current WHO targets [33]. However, we believe
to date that treatment outcomes of MDR-TB, as well as possi-
ble factors related with poor treatment outcomes of MDR-TB,
have not been reported in Sudan. This study aimed to address




A hospital-based study was conducted at Abu-Anga hospital,
which is the specialized hospital in Sudan to which suspected
TB cases are referred to as well as providing health-care ser-
vices to the population of Khartoum and neighboring states.
Abu-Anga hospital is also the main MDR-TB reference hos-
pital where all recording and reporting processes are gathered
and analyzed in Sudan. The hospital in collaboration with the
medical colleges in Sudan and the Ministry of Health also
facilitates training in the management of patients with TB
and provides access to data for research purposes.
2.2. Study design
A combined retrospective and prospective cohort study
design was employed. All MDR-TB patients notified between
January 2013 and September 2017 attending the hospital
were consecutively targeted. Cohorts of 2013, 2014, 2015,
2016, and 2017 were followed up until the end of the treat-
ment period. The cases from 2013, 2014 and 2015 were
Article highlights
● Multidrug-resistant tuberculosis (MDR-TB) has an appreciable socio-
economic impact and threatens global public health. The current
study aimed to assess treatment outcomes of MDR-TB and predictors
of poor treatment outcomes in Sudan.
● All MDR-TB patients with complete records admitted between 2013
and 2017 to a leading TB hospital in the capital of Sudan, Khartoum,
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● Treatment success for patients with MDR-TB (defined by WHO cri-
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of poor outcomes of MDR-TB treatment in this study.
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include instigating more treatment centers in rural areas alongside
programs to enhance adherence including greater patient counseling
especially for patients who have difficulties in reading.
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reviewed retrospectively. Some cases from 2016 and the cases
from 2017 were followed up prospectively until the final out-
comes were reported.
Consequently, data collection was started in August 2017
and ended in April 2019. This study design was adopted as the
MDR-TB population is a relatively small population and needs
a long period for follow-up (i.e. 18 months). Patients were
enrolled in the study if they had bacteriologically proven
resistance to rifampicin and isoniazid or had clinically evident
MDR-TB based on a history of treatment failure or MDR-TB
contact defined according to WHO guidance [36,37]. (Table 1).
The success rate was defined as the sum of cured and com-
pleted patients*100/total cases.
2.3. Molecular screening, treatment regimen, and
monitoring
In 2012, the Sudan national tuberculosis control program (NTP)
started a molecular screening for TB patients by using Hain
MTBDRplus for RIF/INH resistance and MTBDRsl VER 1.0 for fluor-
oquinolones and injectable second-line anti-TB drugs to screen
XDR-TB. In 2014, GeneXpert was launched while MTBDRsl version
2 was brought in during 2017. GeneXpert simultaneously pro-
vides rapid detection of TB and resistance to RIF in less than 2 h.
In terms of molecular screening, previously the national MDR-TB
diagnostic algorithm divided TB presumptive cases into two
groups. The first group was the high-risk group, and patients
must be screened by GeneXpert. This group includes retreat-
ment TB cases, MDR contacts, HIV-positive patients, health-care
workers, and seriously ill patients. The second group includes the
new cases of TB for which screening has not been routinely
undertaken. However, currently, all TB presumptive cases are
screened by GeneXpert including new cases of TB, extra-pulmon-
ary and childhood TB. Sputum smear microscopy was dedicated
to the monitoring of treatment of first-line anti-TB drugs (FLDs).
Currently, both conventional and molecular DST are used for
both FLDs and SLDs as per the NTP guidance. In practice, mole-
cular screening and DST are not routinely performed for SLDs
unless XDR-TB is suspected based on the clinical and microbio-
logical findings. As per the Sudan National TB Management
Guideline, the use of sputum smear microscopy and culture to
monitor response to treatment are both recommended for the
monitoring of patients with MDR-TB [38].
The treatment regimen is selected based on the recommenda-
tions of the NTP, which is based on previous WHO guidelines
[38,39]. All confirmed MDR-TB cases received an 18-month stan-
dardized regimen in two phases: an 8-month intensive and 10-
month continuation phase. Themedications encompassed a com-
bination of first and second-line anti-TBmedicines including kana-
mycin (Km), levofloxacin (Lev), cycloserine (Cs), ethionamide (Eth),
andpyrazinamide (Z). All thesemedicines aregiven in the intensive
phase,while aminoglycoside iswithdrawnduring the continuation
phase [39]. The enrolled MDR-TB patients are treated under two
models of treatment including hospital-based and community-
based; both are directly observed treatment (DOT) regimens.
The direct observation for treatment and monitoring of SLDs
adverse effects is facilitated by a treatment supporters’ network
among community-based enrolled MDR-TB patients which pro-
vides MDR-TB nurses and specialists with weekly reports and a
monthly evaluation regarding second-line anti-TB drug safety.
The patients are routinely monitored for adverse effects espe-
cially for the most common adverse effects associated with SLDs
including gastrointestinal adverse effects, e.g. nausea, vomiting,
etc., psychosis, neurotoxicity, nephrotoxicity, thyroid dysfunc-
tion, or gouty arthritis. To reduce the incidence of these adverse
effects, doses are escalated for SLDs in a period of 4 weeks.
Subsequently, the full doses are gradually built to avoid toxicity
and increase patient tolerance. If toxicity is reported by a treat-
ment supporter, it is evaluated by the medical panel. Either the
concernedmedicine is discontinued till symptoms disappear and
subsequently escalated. Alternatively, the medicines are
replaced by a backup medicine para-aminosalicylic acid (PAS).
The backup regimen is composed of PAS with omitting the
incriminating medicines, either Cs or Eth (they are themost likely
SLDs associated with adverse effects). In the case of Z, the patient
with elevated uric acid is treated from gouty arthritis without
omitting it.
2.4. Treatment outcomes
Treatment outcomes were assigned based on the definition of
WHO as cured, treatment completed, treatment failed, died,
and lost to follow-up (Table 1). Treatment success refers to the
proportion of patients who were taking their full treatment
course for the entire period of treatment and declared cured
or completed, whereas poor treatment outcomes were
defined as the proportion of death, treatment failure, or treat-
ment default out of the total enrolled patients.
Table 1. Definition of TB types, resistance, and final treatment outcomes
according to WHO
Category Definition
Pulmonary TB Lung parenchyma affected by Mycobacterium TB
Extrapulmonary
TB
TB affects body organs other than lung
RR Rifampicin resistance. It also includes other types of
rifampicin resistance like MDR-TB and extensive drug
resistance (XDR)
MDR-TB Isolate of Mycobacterium exhibits resistance to at least
rifampicin and isoniazid
New patients Patient who has never exposed to TB drugs or administer
TB medications for less than one month
Cure Is when at least three consecutive sputum samples taken
at least 30 days apart are negative during the




Patients complete treatment without evidence of three
consecutive sputum samples taken at least 30 days
apart are negative during the continuation phase and
without evidence of treatment failure
Relapse TB patient remains sputum negative during treatment but




Interruption of treatment for at least 2 consecutive months
Treatment
failure
Total change of treatment regimen or at least two drugs
are terminated due to (a) sputum test remains positive
by the end of intensive phase; (b) during continuation
phase, reversion after conversion; (c) adverse drug




Treatment outcome is not assigned. It includes transferred
out cases and those of unknown treatment outcome
Died Recorded as died during treatment course irrespective of
cause
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The outcome of interest for the survival analysis was poor
treatment outcomes, which included death, treatment failure,
or treatment default whichever occurred first. Consequently,
patients were assigned censored if declared as a cure, treat-
ment complete, or transferred out. In cases of censoring, we
considered the survival time of this category starting from the
start of treatment (T0) till the date of being transferred out
(T1), and the date of announcing a cure or treatment complete
(T2). On the other hand, time to event survival time was
computed from T0 up to the date the patient developed the
outcome of interest (i.e. the poor treatment outcome) (Ti) [40].
2.5. Sample size
All patients registered in the hospital between 2013 and 2017
of both genders and with different ages were targeted. A total
of 200 MDR-TB patients were registered during this period;
however, only those with complete records were enrolled in
the study (n = 156 patients; 78%). There was no sampling of
patients because the total number of patients was limited and
thus all patients were recruited.
2.6. Statistical analysis
Data were processed by IBM-SPSS version 24. Statistical tests
such as unpaired t-test, chi-square, and Fischer exact test were
run to summarize continuous and categorical variables of the
sociodemographic and clinical factors. Moreover, the Kaplan–
Meier curve was adopted to specify the cumulative survival
probability. The log-rank test was processed to assess the influ-
ence of different covariates on the survival time of patients.
Cases with event outcome (poor treatment outcomes) were
coded as 1, whereas censored cases were coded as 0 (refer-
ence category).
A bivariate Cox proportional hazard was first processed,
and the significant variables were fitted in the final multivari-
able Cox proportional hazard model. The ninety-five percent
confidence interval (95% CI), crude and adjusted hazard ratios
(HR) were computed to estimate the predictors of time to
poor treatment outcomes. The transferred out category was
excluded from the bivariate and multivariate Cox proportional
hazard model. Ultimately, the predictors were identified and
considered significant at a P-value less than 0.05.
2.7. Ethical approval
Ethical approval number fmoh/nhrc/rd/ec was granted by the
research directorate, Federal Ministry of Health, Sudan (FMOH)
dated 29/07/2017. There was no patient consent form with this
FMOH approval as the source of information was the TB patient
card and TB registry book, with no direct contact with patients.
3. Results
3.1. Socio-demographic characteristics
As mentioned, 156 cases of MDR-TB (78%) were included in the
analysis. The average age of enrolled patients was 35 ± 14 years,
ranging from 15 to 90. Three-quarters of the patients (n = 117,
75%) were male and just over one third (37.5%) lived in rural
locations (Table 2). No statistically significant (P > 0.05) differ-
ences in the socio-demographic characteristics were observed
among the study variables except for residency (Table 2).
3.2. Clinical characteristics
Most of the study sample (n = 152; 97.4%) were smear-positive
pulmonary TB (PTB) whereas there were only four extrapulmon-
ary TB (ETB) cases (2.6%). The number of primary and secondary
resistant TB was 22 (14.1%) and 134 (85.9%), respectively. The
mortality rate among PTB versus ETB patients was 13.8% versus
25%, respectively. The mean hemoglobin concentration of the
event category was 15.4 mg/dl ± 1.3, whereas among the cen-
sored group this was found to be 14.0 ± 2.1.
The mean level of serum creatinine was assessed to be almost
the same in both event and censored categories (0.7 mg/dl). All
HIV/AIDS cases (n = 3) included in the study were in the censored
group and all were on antiretroviral therapy (ART) (Table 3).
Ultimately, there were no statistically significant differences
between the two groups in terms of clinical factors except for
previous treatment outcome (P < 0.05) and previous exposure to
SLDs (P = 0.04) (Table 3).















15–34 97 (62.2) 35 (63.6) 62 (61.4) 0.91
35–54 40 (25.6) 13 (23.6) 27 (26.7)
≥55 19 (12.2) 7 (12.7) 12 (11.9)
Sex
Male 117 (75.0) 43 (78.2) 74 (73.3) 0.50
Female 39 (25.0) 12 (21.8) 27 (26.7)
Marital status 149
Single 69 (51.1) 21 (43.8) 48 (55.2) 0.20
Married 66 (48.9) 27 (56.3) 39 (44.8)
Occupation
Employee 11 (7.1) 5 (9.1) 6 (6.1)
Self-employed 45 (29.2) 14 (25.5) 31 (31.3) 0.63
Without job 98 (63.6) 36 (65.5) 62 (62.6)
Residency
Rural 57 (37.5) 31 (57.4) 26 (26.5) <0.05*
Urban 95 (62.5) 23 (42.6) 72 (73.5)
Number of family
members
≤3 23 (21.3) 7 (20.6) 16 (21.6)
4– 6 36 (33.3) 8 (23.5) 28 (37.8) 0.27
>6 49 (45.4) 19 (55.9) 30 (40.5)
Nationality
Sudanese 137 (87.8) 46 (83.6) 91 (90.1)
South Sudan 5 (3.2) 2 (3.6) 3 (3.0) 0.43
Others 14 (9.0) 7 (12.7) 7 (6.9)
Treatment
supporterc
Yes 31 (19.9) 14 (25.5) 17 (16.8) 0.29
No 106 (67.9) 33 (60.0) 73 (72.3)
Not recorded 19 (12.2) 8 (14.5) 11 (10.9)
NB: The P-value was taken from the Pearson’s chi-square (χ2) test or Fisher’s
exact test. * = statistical significance; not all variables add up to 156 due to
missing data
aEvent in this study was either death or treatment failure or treatment default.
bCensored was either cured or completed or transferred out.
cTreatment supporter is the person, i.e. family member, friend or colleague, who
takes care of the TB patients.
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3.3. Treatment outcomes
The treatment outcomes were broken down into successful treat-
ment (cure and treatment complete), poor outcomes (died, treat-
ment failure or defaulters) and the transferred out-group – Table 4.
Of the 156 MDR-TB patients, 26 (16.7%) were cured, 73 (44.2%)
completed the treatment, 22 (14.1%) died, 30 (19.2%) defaulted on
treatment, three (1.9%) were treatment failures and two (1.3%)
were transferred out (Table 4).
Consequently, the number of patients with successful treat-
ment outcomes was 99, giving an overall success rate of
63.5%. Poor treatment outcomes were observed to be signifi-
cantly associated with rural residency as compared with those
living in urban facilities (P < 0.05) (Table 4).
3.4. Survival time and treatment outcomes during the
follow-up period
The mean survival time for the different categories (i.e. treat-
ment outcomes) during the study period was noted to be
significantly shorter among dead and defaulted cases (5
months), whereas relatively longer among treatment failures
(15 months) (P < 0.05) (Figure 1).
3.5. The pattern of success rate over the years
The pattern of the success rate was seen to be increasing
between 2013 and 2016; however, decreasing after that.
Overall, the rate of success rates was 53.3%, 59.1%, 66.7%,








(n = 101) P-value
Site of disease
Pulmonary 152 (97.4) 54 (98.2) 98 (97.0)
Extrapulmonary 4 (2.6) 1 (1.8) 3 (3.0) >0.05
Number of previous TB infection
New 22 (14.1) 6 (10.9) 16 (15.8)
Once 74 (47.4) 25 (45.5) 49 (48.5) 0.51
Twice 53 (34.0) 20 (36.4) 33 (32.7)
Thrice and above 7 (4.5) 4 (7.3) 3 (3.0)
Previous treatment outcomec
Treatment failure 147 (96.1) 48 (88.9) 99 (100.0)
Defaulter 1 (0.7) 1 (1.9) 0 (0.0) <0.05*
Relapse 5 (3.3) 5 (9.3) 0 (0.0)
HIV/AIDS
Positive 3 (1.9) 0 (0.0) 3 (3.0)
Negative 153 (98.1) 55 (100.0) 98 (97.0) 0.55
History of second-line anti-TB
Positive 3 (1.9) 3 (5.5) 0 (0.0) <0.05*
Negative 153 (98.1) 52 (94.5) 101 (100)
History of diabetes mellitus
Positive 6 (3.8) 1 (1.8) 5 (5.0) 0.13
Negative 2 (1.3) 2 (3.6) 0 (0.0)
Not recorded 148 (94.9) 52 (94.5) 96 (95.0)
Treatment side effects
Positive 55(35.3) 19 (34.5) 36 (35.6) 0.89
Negative 101 (64.7) 36 (65.5) 65 (64.4)
Initial culture result
Positive 141 (90.4) 48 (87.3) 93 (92.1) 0.59
Negative 4 (2.6) 2 (3.6) 2 (2.0)
Not recorded 11 (7.1) 5 (9.1) 6 (5.9)
Hemoglobin, mean ± SD 14.0 ± 2.0 15.4 ± 1.3 14.0 ± 2.1 0.15
Creatinine (mmol/l), mean ± SD 0.7 ± 0.5 0.7 ± 0.1 0.7 ± 0.5 0.80
White blood cell count, mean ± SD 7200 ± 2300 6200 ± 1900 6400 ± 2400 0.29
NB: The P-value was taken from the Pearson’s chi-square (ꭓ2) test or Fisher’s exact test or unpaired t-test. * = statistical significance.
aEvent in this study was either death or treatment failure or treatment default
bCensored was either cured, completed, or transferred out.
cThe outcome was missing in three cases.
Table 4. Treatment outcomes of patients with multidrug-resistant tuberculosis grouped by residency status and previous treatment outcome.
Status Residency Previous treatment outcome
Treatment outcome
Total patients
n = 156 (%)
Rural
n = 57 (%)
Non-rural






Cured 26 (16.7) 8 (14.0) 18 (18.9) 25 (17.0) - -
Completed 73 (44.2) 17 (29.8) 53 (55.8) 73 (49.7) - -
Transferred out 2 (1.3) 1 (1.8) 1 (1.1) 1 (0.7) - -
Poor outcome
Died 22 (14.1) 10 (17.5) 11 (11.6) 20 (13.6) 2 (40) -
Treatment failure 3 (1.9) 2 (3.5) 1 (1.1) 2 (1.4) - 1 (100.0)
Defaulted 30 (19.2) 19 (33.3) 11 (11.6) 26 (17.7) 3 (60) -
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and 73.1% in 2013, 2014, 2015, and 2016, respectively, before
decreasing to 60% in 2017 (Figure 2).
3.6. The probability survival of MDR-TB patients
All the study participants were followed for a median of 18
months [Inter quartile range (IQR): 6 to 18 months] and a total
of 2108 person-months. A total of 55 poor treatment events were
reported during the study period. These included 22 deaths, 30
defaulters, and three failures that yield 26 poor outcomes per
1000 person-months (Figure 3).
MDR-TB patients living in rural areas had significantly shorter
survival times comparedwith those living inurban facilities (11 and
15 months, P < 0.05, respectively). The cumulative probability of
survival at the end of the study period among rural residents and
urban was noted to be 45% and 76%, respectively (Figure 4).
3.7. Predictors of poor MDR-TB treatment outcomes
On bivariate analysis, rural residency and being a relapse patient
from previous treatments were significantly associated with poor
MDR-TB treatment outcomes (Table 5).
Figure 1. Schematic of survival time and treatment outcomes during the follow-up period.
Figure 2. Number of MDR-TB patients, successful treatment outcomes, and poor treatment outcomes grouped by year.
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Furthermore, multivariate analysis showed that the same fac-
tors, i.e. being rural and relapses from previous treatments, were
significantly associated with a poor outcome from treating MDR-
TB. Rural residents had more than twice the risk of a poor treat-
ment outcome (AHR = 2.5, 95 CI: 1.4–4.58). Similarly, a relapsed
patient from the previous treatments was five times more likely
to have a poor treatment outcome (AHR = 4.9, 95% CI: 1.8–12.9)
(Table 6).
4. Discussion
Our study aimed to assess the treatment outcomes of MDR-TB
patients at the leading TB hospital in Sudan and to assess the
determinants of poor treatment outcomes. Identifying these
determinants in a high prevalence country such as Sudan should
help improve the overall performance of the TB program. As a
result, reducing future morbidity and mortality associated with
MDR-TB. This could be achieved by the instigation of pertinent
interventions and strategies that will help to successfully
improve treatment outcomes in the future building on the
recent changes in suggested regimens by the WHO [18].
By 2015, the Stop TB Partnership Global Plan stated that
one million MDR-TB patients worldwide were to be targeted
with respect to detection and treatment coverage. Moreover,
success rates of at least 75% need to be achieved as the global
target [17,41]. Our study shows that the overall success rate of
63.5% was lower than the 2015 global target [17]. Having said
this, the treatment success rate of MDR-TB patients in our
study was comparable to other low-resource countries such
as Egypt (69.3%) [42] and Pakistan (71.6%) [43], although
lower than high-income countries such as the United States
(78%) [44], and Switzerland (76%) [45]. There was an improve-
ment in the pattern of success rates from 2013 up to 2016;
however, unfortunately, this declined to only 60% in 2017
(Figure 2). This decline could be due to recent political and
economic issues in Sudan that severely affected the healthcare
system [46]. However, further research is needed before we
can say this with certainty. In view of this decline in this high
priority disease area, we believe there is an urgent need for
the health authorities in Sudan to take the initiative and
maximize efforts and resources to achieve the global target
of a 75% success rate for MDR-TB, and we will be making a
number of suggestions under recommendations.
Our findings that patients living in rural areas had poorer
treatment outcomes are similar to the findings of Ali and Prins
[35]. Poorer outcomes could potentially be attributed to the
distance to the treatment center and the cost of transporta-
tion despite the medicines being provided free of charge. We
have seen this phenomenon in studies assessing factors
impacting on adherence to antihypertensive medicines
[47,48]. However, few studies to date have described the
association between residency and poor treatment outcomes
among patients with MDR-TB. Similar to our findings, a case–
control study undertaken in Khartoum state investigating the
factors associated with treatment interruption among TB
patients also reported that rural residency was significantly
associated with treatment default in Sudanese patients [49].
In this study, patients recorded as relapses were five times as
likely to have poor treatment outcomes. Ahmed et al. also
concluded that a poor previous treatment outcome was also
significantly correlated with treatment default among
Sudanese patients [49]. Chen et al. also found that 65% of
Figure 3. Kaplan–Meier curve showing the probability survival of MDR-TB patients since the commencement of treatment to end of the study period.
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MDR-TB cases had poor treatment outcomes including
relapses before becoming MDR-TB. Moreover, unlike new
cases, chest radiograph findings of re-treated cases revealed
significantly more cavitation when compared to new cases
[50]. In contrast, our regression model did not predict any
association between most of the sociodemographic factors
and the time to poor MDR-TB treatment outcomes (Table 5).
These findings though are consistent with a number of other
studies that confirmed no association for instance with gender
or age and poor MDR-TB treatment outcomes [51–53].
On the other hand, anemia was not found to impact on
poor treatment outcomes in our study. This is unlike Alene et
al. who found that anemic patients were more than twice as
likely to have poor treatment outcomes from their MDR-TB
[40]. The positive association between anemia and death
among MDR-TB patients has also been reported in a number
of other published studies [54–56]. This association could be
attributed to delayed presentation [40]. Despite this, the
National TB program (NTP) in Sudan has recently introduced
investigations including complete blood count (CBC) as a
routine before treatment to help improve the outcomes in
these patients, and we will be investigating this further in
future studies.
Previous exposure to SLDs including fluoroquinolones and
aminoglycosides was not associated with poor treatment out-
comes in our study. However, the findings of a prospective
cohort study undertaken in eight countries suggested that the
rate of resistance to SLDs and the precipitation of extensive
drug resistance-TB (XDR-TB) were seen among those patients
who were previously prescribed SLDs [57]. Consequently,
increased prescribing of SLD such as amikacin and ofloxacin
for infectious diseases other than TB might increase the inci-
dence of XDR-TB. As a result, we will be researching potential
ways to reduce their prescribing in future studies in Sudan.
We know that the rate of treatment failure and death of
patients with MDR-TB are associated with clinical factors as
well as sociodemographic factors, which include unemploy-
ment, imprisonment, and alcoholism [58]. Our findings sug-
gest that 19 out of 30 defaulters were rural residents (Table
4). Moreover, 65.5% of poor MDR-TB outcome events were
seen in unemployed patients (Table 2). Consequently, we
will be looking at a number of different measures to
improve patient adherence in the future including home
visits, disability stipends, monthly incentives, and assistance
with transportation costs. In addition, looking at potential
changes in treatment regimens following changes in WHO
recommendations [18]. This will be the subject of future
research projects. We will also be investigating issues of
education as this can impact on issues of adherence and
treatment ourtcomes in these patients [59,60].
The current study included only three patients with HIV/AIDS
(Table 3). However,we are aware thatHIV/AIDS contributes topoor
treatment outcomes [3,13,54], and that patients taking ART have a
lower risk of dying [5]. Girum et al. found that HIV/AIDS positive
patients with MDR-TB were three times more liable to die com-
paredwith seronegative patients [61]. This ismost probably due to
severe interactions between SLDs andART, and the accompanying
adverse effects which in turn might affect patient’s adherence to
treatment. Moreover, independent predictors of failure and death
such as age, HIV/AIDS, comorbidities, and persistent positive cul-
tures by the thirdmonth of treatment should draw the attention of
clinicians to examine the potential for additional interventions.
Figure 4. Kaplan–Meier survival probability curve for rural and urban MDR-TB patients.
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Older age, HIV/AIDS, and the frequency of XDR-TB increase the
death rate among TB patients [62]. SLDs are more toxic when
compared with first-line anti-TB treatments, and this might also
affect patient adherence [63]. The adverse effects comprise gastro-
intestinal (GI) disturbances, psychosis, peripheral neuropsychiatric
disorders, and hearing disturbance [54]. Consequently, adverse
effects need to be considered by clinicians when prescribing
medicines for patients with MDR-TB, and necessary interventions
should also be considered to improve adherence rates.
Interventions could include greater education of patients regard-
ing the different regimens and the need to complete the course of
treatment, particularly among those patients with more limited
education.
We are aware that there are several limitations to this
study. Firstly, the information in some patient cards was
often incomplete. In addition, information was only col-
lected once during the study period. We also did not con-
sider other sociodemographic and clinical factors impacting
on outcomes including smoking, alcohol, asthma, heart dis-
eases, and drug addiction as the primary source of data was
the patient cards. In addition, the immunovirological status
of HIV-patients was not considered in this study because
the test data were not recorded in TB registries. The study
scope focused on the treatment outcomes of MDR-TB
patients and the factors associated with poor treatment
outcomes, and provided useful data for future guidance of
these patients in Sudan given the limited data to date in
this important area. However, other aspects such as the
adverse reactions of drugs used to treat patients with
MDR-TB was out of the scope of this study. Future studies
will though be undertaken to explore this aspect further.
Despite these limitations, we believe our findings are robust
in view of the fact that this is the leading hospital treating
MDR-TB patients in Sudan and we included all the patients
during the period of 2013–2017.
5. Conclusion and recommendations
In conclusion, we believe based on our findings that the current
situation of TB in general and MDR-TB, in particular, in Sudan is a
concern especially with a decline in the success rate of MDR-TB in
recent years. We also ascertained that patients living in rural areas
and relapse patients from previous treatments were associated
with poorer outcomes.
In view of our findings, we recommend more care to be
given to MDR-TB patient groups that are highly susceptible to
death and default in Sudan, which should include greater
educational input especially in those patients with limited
education. Moreover, it is highly recommended that the
authorities in Sudan continue to maintain total coverage of
the drug supply for all MDR-TB patients for the entire period of
their treatment. The authorities should also look to instigate
more treatment centers in rural areas alongside programs to
enhance adherence to prescribed treatments including patient
counseling. We will be exploring these options in the Ministry
of Health in the coming months alongside their other priority
areas. Moreover, in light of these findings and as Sudan is
lacking behind the global target, further studies are recom-
mended to tackle other variable aspects and barriers to suc-
cessful MDR-TB treatment outcomes in Sudan. We will also be
pursuing these as well with relevant personnel and authorities
Table 5. Bivariate–Cox regression analysis of determinants for time to poor









Male 43/116 (37.1) 1.2 (0.7–2.4) 0.50
Female 12/38 (31.6) 1
Residency
Rural 31/56 (55.4) 2.8 (1.6–4.8) <0.05*
Urban 23/94 (24.5) 1
Marital status
Married 27/66 (40.9) 1.4 (0.8–2.5) 0.23
Single 21/68 (30.9) 1
Occupation of
the patient
Without work 36/96 (37.5) 0.73 (0.3–1.8) 0.50
Self-employed 14/45 (31.1) 0.6 (0.2–1.7) 0.35
Employee 5/11 (45.5) 1
Treatment
supporter
Not recorded 8/19 (42.1) 1
No 33/104 (31.7) 0.6 (0.3–1.3) 0.20




Relapse 5/5 (100) 8.2 (3.2–21.1) <0.05*
Defaulter 1/1 (100) 2.6 (0.4–19.1) 0.34




Positive 3/3 (100) 2.6 (0.8–8.4) 0.10




Positive 1/6 (16.7) 0.4 (0.1–3.1) 0.39
Negative 2/2 (100) 3.9 (0.9–15.9) 0.06
Not recorded 51/140 (36.4) 1
HIV/AIDS
Positive 0/3 (0.0) 0.0 (0.0–116.7) 0.45
Negative 55/151 (36.4) 1
Hemaglobin
status
Anemic 0/8 (0.0) 0.0 (0.0–495.7) 0.49
Normal 5/34 (14.7) 1
NB: In this analysis, two transferred outpatients were excluded from the
analysis. * = statistical significance
aValues are poor treatment outcome/total number of patients in the category
(%)
Table 6. Multivariate Cox regression analysis of determinants for time to poor









Rural 31/56 (55.4) 2.5 (1.4–4.58) <0.05*




Relapse 5/5 (100) 4.9 (1.8–12.9) <0.05*
Defaulter 1/1 (100) 1.5 (0.2–11.3) 0.68
Treatment failure 48/146 (32.9) 1
aIn this analysis, two transferred outpatients were excluded from the analysis.
* = statistical significance
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in Sudan and reporting on developments and their impact in
the future.
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